Abstract
Background: Hypothyroidism, characterised by low/normal free thyroxine (FT4) and free triiodothyronine (FT3) with elevated thyroid-stimulating hormone (TSH), is a well-known complication of nephrotic syndrome (NS). This is a common feature of primary and secondary glomerular diseases and comprises loss of protein in the urine and increased urinary excretion of thyroid hormones and thyroxine- binding globulin. With a normal thyroid reserve, this scenario is associated with the development of subclinical hypothyroidism, with a slight increase in TSH and normal free fractions. However, with a low thyroid reserve the transition toward overt hypothyroidism is almost inevitable, affecting morbidity and mortality. As T4 replacement is a cheap and well-established treatment to achieve a stable hormone status in different types of thyroid deficiency, it is essential to recognise and appropriately treat this condition.
Conclusion: In this article we summarise the evidence on this nephro-endocrine disorder in humans and focus on diagnostic and therapeutic strategies.Keywords: Nephrotic syndrome, hypothyroidism, glomerulonephritis, thyroid hormones, replacement, treatment.
Current Vascular Pharmacology
Title:Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Volume: 15 Issue: 5
Author(s): F. Di Mario, R. Pofi, A. Gigante*, L. Rivoli, E. Rosato, A. M. Isidori, R. Cianci and B. Barbano
Affiliation:
- Department of Clinical Medicine, Sapienza, University of Rome, Viale dell’Università, 37, 00185 Rome,Italy
Keywords: Nephrotic syndrome, hypothyroidism, glomerulonephritis, thyroid hormones, replacement, treatment.
Abstract: Background: Hypothyroidism, characterised by low/normal free thyroxine (FT4) and free triiodothyronine (FT3) with elevated thyroid-stimulating hormone (TSH), is a well-known complication of nephrotic syndrome (NS). This is a common feature of primary and secondary glomerular diseases and comprises loss of protein in the urine and increased urinary excretion of thyroid hormones and thyroxine- binding globulin. With a normal thyroid reserve, this scenario is associated with the development of subclinical hypothyroidism, with a slight increase in TSH and normal free fractions. However, with a low thyroid reserve the transition toward overt hypothyroidism is almost inevitable, affecting morbidity and mortality. As T4 replacement is a cheap and well-established treatment to achieve a stable hormone status in different types of thyroid deficiency, it is essential to recognise and appropriately treat this condition.
Conclusion: In this article we summarise the evidence on this nephro-endocrine disorder in humans and focus on diagnostic and therapeutic strategies.Export Options
About this article
Cite this article as:
Mario Di F., Pofi R., Gigante A.*, Rivoli L., Rosato E., Isidori M. A., Cianci R. and Barbano B., Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat, Current Vascular Pharmacology 2017; 15 (5) . https://dx.doi.org/10.2174/1570161115999170207114706
DOI https://dx.doi.org/10.2174/1570161115999170207114706 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in the Field of Quinazoline Chemistry
Current Organic Chemistry Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Editorial
Recent Patents on Food, Nutrition & Agriculture Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases - Part II
Current Medicinal Chemistry Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract
Current Pharmaceutical Design Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry A Review of Type 2 Diabetes Mellitus Predisposing Genes
Current Diabetes Reviews MiR-218-5p Mediates Myocardial Fibrosis after Myocardial Infarction by Targeting CX43
Current Pharmaceutical Design Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Differential Effects of Trans and Polyunsaturated Fatty Acids on Ischemia/ Reperfusion Injury and its Associated Cardiovascular Disease States
Current Pharmaceutical Design Current and Future Therapeutic Strategies in NAFLD
Current Pharmaceutical Design Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Lipoprotein (a) Management: Lifestyle and Hormones
Current Medicinal Chemistry Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies
Cardiovascular & Hematological Disorders-Drug Targets Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents